Kreck, Simon; Klaus, Jochen; Leidl, Reiner; Tirpitz, … - In: PharmacoEconomics 26 (2008) 4, pp. 311-328
The ibandronate strategy is unlikely to be considered cost effective by decision makers in men or women with characteristics of those in the target population of the RCT, or in older populations with osteoporosis. </AbstractSection> Copyright Adis Data Information BV 2008